Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin
Completed
- Conditions
- Undifferentiated Arthritis
- Registration Number
- NCT03466814
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
Observational study of abatacept in the treatment of JIA in Japan.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
- All JIA participants who initiate treatment with Orencia in accordance with the prescribing information
Exclusion Criteria
- Participants receiving Orencia for an off-label indication
Other protocol defined inclusion/exclusion criteria could apply
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of adverse events 1 year
- Secondary Outcome Measures
Name Time Method Safety measured by number of participants who receive at least 1 dose of Orencia 1 year Efficacy measured by number of participants who receive at least 1 dose of Orencia 1 Year
Trial Locations
- Locations (1)
Local Institution
🇯🇵Shinjuku-ku, Tokyo, Japan
Local Institution🇯🇵Shinjuku-ku, Tokyo, Japan